CY1121368T1 - Αντισωματα anti-asic1 και χρησεις αυτων - Google Patents

Αντισωματα anti-asic1 και χρησεις αυτων

Info

Publication number
CY1121368T1
CY1121368T1 CY20191100246T CY191100246T CY1121368T1 CY 1121368 T1 CY1121368 T1 CY 1121368T1 CY 20191100246 T CY20191100246 T CY 20191100246T CY 191100246 T CY191100246 T CY 191100246T CY 1121368 T1 CY1121368 T1 CY 1121368T1
Authority
CY
Cyprus
Prior art keywords
asic1
antibodies
cells expressing
induced
acid
Prior art date
Application number
CY20191100246T
Other languages
English (en)
Inventor
Lynn Macdonald
Min Gao
Marc. R. MORRA
Nicole M. Alessandri Haber
Michael L. Lacroix-Fralish
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121368(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1121368T1 publication Critical patent/CY1121368T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει αντισώματα και αντιγονοδεσμευτικά θραύσματα αυτών τα οποία δεσμεύονται ειδικά σε κύτταρα που εκφράζουν τον δίαυλο ιόντων αίσθησης οξέων 1 (ASIC1). Σύμφωνα με ορισμένες υλοποιήσεις της εφεύρεσης, τα αντισώματα αναστέλλουν τα επαγόμενα από οξέα, προκαλούμενα από τον ASIC1 ιοντικά ρεύματα στα κύτταρα που εκφράζουν τον ανθρώπινο ASIC1. Τα αντισώματα της εφεύρεσης είναι χρήσιμα για τη θεραπεία του πόνου, συμπεριλαμβανομένου του πόνου που σχετίζεται με χειρουργική επέμβαση, καθώς και με διάφορες νόσους και διαταραχές.
CY20191100246T 2012-01-31 2019-02-27 Αντισωματα anti-asic1 και χρησεις αυτων CY1121368T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US201261692925P 2012-08-24 2012-08-24
PCT/US2013/023784 WO2013116296A1 (en) 2012-01-31 2013-01-30 Anti-asic1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CY1121368T1 true CY1121368T1 (el) 2020-05-29

Family

ID=47666522

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100246T CY1121368T1 (el) 2012-01-31 2019-02-27 Αντισωματα anti-asic1 και χρησεις αυτων
CY20211100968T CY1124778T1 (el) 2012-01-31 2021-11-09 Αντισωματα anti-asic1 και χρησεις αυτων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100968T CY1124778T1 (el) 2012-01-31 2021-11-09 Αντισωματα anti-asic1 και χρησεις αυτων

Country Status (33)

Country Link
US (3) US9150648B2 (el)
EP (2) EP3453723B1 (el)
JP (1) JP6302844B2 (el)
KR (1) KR102111941B1 (el)
CN (1) CN104093738B (el)
AR (1) AR089852A1 (el)
AU (1) AU2013215254B2 (el)
CA (1) CA2862332C (el)
CL (1) CL2014002019A1 (el)
CO (1) CO7020877A2 (el)
CY (2) CY1121368T1 (el)
DK (2) DK2809681T3 (el)
EA (1) EA028647B1 (el)
ES (2) ES2886123T3 (el)
HK (1) HK1199269A1 (el)
HR (2) HRP20211541T1 (el)
HU (2) HUE042531T2 (el)
IL (2) IL233410A0 (el)
IN (1) IN2014CN04645A (el)
JO (1) JO3547B1 (el)
LT (2) LT2809681T (el)
MX (1) MX358518B (el)
MY (1) MY168748A (el)
NZ (1) NZ626242A (el)
PH (1) PH12014501613B1 (el)
PL (2) PL3453723T3 (el)
PT (2) PT2809681T (el)
RS (2) RS58439B1 (el)
SG (1) SG11201403222UA (el)
SI (2) SI2809681T1 (el)
TW (1) TWI591073B (el)
UY (1) UY34603A (el)
WO (1) WO2013116296A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3547B1 (ar) 2012-01-31 2020-07-05 Regeneron Pharma أجسام مضادة ضد تخليق جدار الخلية واستعمالاتها
JP2017513854A (ja) * 2014-04-15 2017-06-01 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｗｉｓｐ１に結合する抗原結合タンパク質
MX2016014926A (es) 2014-05-16 2017-05-09 Ablynx Nv Dominios variables de inmunoglobulina mejorados.
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
PL3638698T3 (pl) * 2018-01-26 2021-09-06 Regeneron Pharmaceuticals, Inc. Przeciwciała i fragmenty wiążące antygen anty-TMPRSS2
AU2019449475A1 (en) * 2019-06-04 2022-01-06 Shanghaitech University Affinity-maturated anti-ASIC1a antibodies
EP3997127A4 (en) * 2019-07-11 2023-08-23 Memorial Sloan Kettering Cancer Center ANTIBODIES TARGETING DLL3 AND THEIR USES
KR20220050127A (ko) * 2019-07-23 2022-04-22 상하이테크 유니버시티 Asic1 채널 안타고니스트 항체
BR112022004603A2 (pt) * 2019-09-13 2022-08-02 Memorial Sloan Kettering Cancer Center Anticorpo anti-cd371 ou um fragmento de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico, vetor de expressão, célula hospedeira, métodos e kit
MX2024001808A (es) * 2021-08-09 2024-02-29 Merck Patent Gmbh Proteinas que desacoplan la citotoxicidad tumoral mediada por celulas t de la liberacion de citoquinas proinflamatorias.
EP4396224A1 (en) * 2021-09-02 2024-07-10 Memorial Sloan Kettering Cancer Center Anti-dll3 antibodies and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
ES2279583T3 (es) 1997-10-29 2007-08-16 Mcgill University Adn que codifica para un canal ionico regulado por protones humano y usos del mismo.
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) * 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
WO2005025518A2 (en) * 2003-09-11 2005-03-24 The Uab Research Foundation Inhibition of inward sodium currents in cancer
US20070281986A1 (en) 2004-02-03 2007-12-06 Collier Gregory R Methods and Compositions for Modulating Satiety
WO2006038070A2 (en) 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
RS52036B (en) * 2004-12-21 2012-04-30 Medimmune Limited ANGIOPOETIN-2 ANTIBODIES AND ITS USES
EP1877444A2 (en) * 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
PL2041177T3 (pl) * 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
EP2975057A1 (en) * 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
US8618113B2 (en) 2006-07-14 2013-12-31 Medical Research Council Treatment for demyelinating disease
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
DK2137539T3 (da) 2007-04-03 2011-01-24 Ilegusavnid Genetics Resource Ct Minestry Of Social Affairs And Health Amolorid følsomme calciumkanaler forbundet med paniklidelser
EP2150564A2 (en) * 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2853897A1 (en) * 2008-05-08 2015-04-01 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
EP2356270B1 (en) * 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
JO3547B1 (ar) 2012-01-31 2020-07-05 Regeneron Pharma أجسام مضادة ضد تخليق جدار الخلية واستعمالاتها

Also Published As

Publication number Publication date
SG11201403222UA (en) 2014-07-30
CL2014002019A1 (es) 2015-01-16
JP6302844B2 (ja) 2018-03-28
SI2809681T1 (sl) 2019-04-30
PT2809681T (pt) 2019-02-18
IL233410A0 (en) 2014-08-31
HUE056335T2 (hu) 2022-02-28
US9150648B2 (en) 2015-10-06
HRP20211541T1 (hr) 2021-12-24
PL3453723T3 (pl) 2022-01-03
CY1124778T1 (el) 2022-11-25
IL254416A0 (en) 2017-11-30
EP3453723A2 (en) 2019-03-13
EP2809681A1 (en) 2014-12-10
US20180222976A1 (en) 2018-08-09
ES2886123T3 (es) 2021-12-16
AR089852A1 (es) 2014-09-24
PT3453723T (pt) 2021-09-07
JO3547B1 (ar) 2020-07-05
HRP20190358T1 (hr) 2019-04-05
EA201491452A1 (ru) 2014-11-28
IN2014CN04645A (el) 2015-09-18
MX358518B (es) 2018-08-24
LT2809681T (lt) 2019-02-11
CN104093738B (zh) 2018-05-18
CA2862332A1 (en) 2013-08-08
PL2809681T3 (pl) 2019-05-31
US20160002332A1 (en) 2016-01-07
CO7020877A2 (es) 2014-08-11
EA028647B1 (ru) 2017-12-29
HK1199269A1 (en) 2015-06-26
MX2014008541A (es) 2014-10-24
EP3453723A3 (en) 2019-04-10
EP3453723B1 (en) 2021-08-11
RS62454B1 (sr) 2021-11-30
NZ626242A (en) 2017-02-24
ES2707599T3 (es) 2019-04-04
RS58439B1 (sr) 2019-04-30
PH12014501613A1 (en) 2014-10-13
KR20140125363A (ko) 2014-10-28
CA2862332C (en) 2021-05-18
DK2809681T3 (en) 2019-03-11
HUE042531T2 (hu) 2019-07-29
EP2809681B1 (en) 2018-12-05
TWI591073B (zh) 2017-07-11
KR102111941B1 (ko) 2020-05-18
US20130195878A1 (en) 2013-08-01
SI3453723T1 (sl) 2021-11-30
UY34603A (es) 2013-07-31
WO2013116296A1 (en) 2013-08-08
JP2015508063A (ja) 2015-03-16
PH12014501613B1 (en) 2014-10-13
DK3453723T3 (da) 2021-09-13
LT3453723T (lt) 2021-09-10
CN104093738A (zh) 2014-10-08
IL254416B (en) 2018-03-29
MY168748A (en) 2018-11-30
US10513557B2 (en) 2019-12-24
TW201335182A (zh) 2013-09-01
AU2013215254B2 (en) 2017-08-31
BR112014018651A2 (pt) 2017-07-04
AU2013215254A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
CY1121368T1 (el) Αντισωματα anti-asic1 και χρησεις αυτων
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1121097T1 (el) Ανθρωπινα αντισωματα κατα toy gfr 3 και μεθοδοι χρησης αυτων
CY1122800T1 (el) Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
CY1124412T1 (el) Aνti-dkk-1 αντισωματα
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
CY1120337T1 (el) Θειοοξικες ενωσεις, συνθεσεις και μεθοδοι χρησης
CY1118714T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
CY1119123T1 (el) Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους
CY1121736T1 (el) Άλατα aramchol
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY1118588T1 (el) Νεα 5-αμινοτετραϋδροκινολινο-2-καρβοξυλικα οξεα και η χρηση τους
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1123485T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια νοσων
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
CY1125102T1 (el) Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης
BR112018068678A2 (pt) anticorpos anti-mica
CY1116940T1 (el) Φλυκταινες εμπλουτισμενες σε φωσφολιπιδιο που φερουν παραγοντα ιστου εχουσες αιμοστατικες δραστικοτητες και χρησεις αυτων
EA201890941A1 (ru) Программируемые универсальные клеточные рецепторы и способы их применения
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora